- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04530565
Testa användningen av steroider och tyrosinkinashämmare med Blinatumomab eller kemoterapi för nydiagnostiserade BCR-ABL-positiv akut lymfoblastisk leukemi hos vuxna
En randomiserad fas III-studie av steroider + tyrosinkinashämmare (TKI) induktion med kemoterapi eller blinatumomab för nydiagnostiserad BCR-ABL-positiv akut lymfatisk leukemi (ALL) hos vuxna
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Studieöversikt
Status
Intervention / Behandling
- Läkemedel: Cyclophosphamide
- Läkemedel: Doxorubicin Hydrochloride
- Läkemedel: Prednisone
- Läkemedel: Ponatinib Hydrochloride
- Läkemedel: Vincristine Sulfate
- Procedur: Echocardiography Test
- Procedur: Multigated Acquisition Scan
- Biologisk: Blinatumomab
- Procedur: Lumbar Puncture
- Läkemedel: Dasatinib
- Procedur: Biospecimen Collection
- Läkemedel: Dexamethasone
- Procedur: Bone Marrow Aspiration and Biopsy
- Procedur: Electrocardiography
- Läkemedel: Cytarabine
- Läkemedel: Mesna
- Läkemedel: Methotrexate
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To compare the overall survival (OS) following induction with steroids + TKI + blinatumomab versus induction with steroids + TKI + chemotherapy.
SECONDARY OBJECTIVES:
I. To compare the rate of minimal residual disease (MRD) negative complete remission (CR) for patients treated with chemotherapy versus (vs) blinatumomab at the end of first induction (week 15).
II. To evaluate the rate of the MRD negative CR by treatment arm for those patients MRD positive after the first induction and administered of second induction.
III. To compare event free survival (EFS) for patients initially randomized for chemotherapy vs blinatumomab.
IV. To assess the toxicities of blinatumomab + TKI vs. TKI + chemotherapy in this patient population.
V. To assess the toxicities of the chemotherapy regimen in this patient population.
VI. To describe the outcome of patients who proceed to allogeneic stem cell transplant after treatment with blinatumomab + TKI only.
OUTLINE:
ARM A (PRE-INDUCTION): Patients receive prednisone orally (PO) once daily (QD) on days 1-21 and ponatinib hydrochloride (ponatinib) PO QD or dasatinib PO QD on days 1-21 based on investigator's choice.
Patients are randomized to 1 of 2 arms (Arm B or C). Patients undergo bone marrow aspiration with biopsy, lumbar punctures, echocardiogram (ECHO), and multigated acquisition (MUGA) scans as indicated by investigator.
ARM B (INDUCTION THERAPY):
CYCLE 1: Patients receive cyclophosphamide intravenously (IV) twice daily (BID) on days 1-3, dexamethasone PO or IV on days 1-4 and 11-14, cytarabine intrathecally (IT) on day 1, doxorubicin hydrochloride (doxorubicin) IV on day 4, vincristine sulfate (vincristine) IV on days 4 and 11, and methotrexate IT on day 8. Patients also receive Mesna 600mg/m^2 IV as a 'chemoprotectant' via continuous infusion on days 1-3, (beginning 1 hour prior to cyclophosphamide and completed by 12 hours after the last dose of cyclophosphamide).
CYCLE 2 (AGE 18-70): Starting in cycle 2, fit patients aged 18-70 receive dasatinib 70mg/day PO QD or ponatinib 30mg/day PO QD on days 1-21, methotrexate IV over 24 hours and IT on day 1, and cytarabine IV over 2 hours BID on days 2-3 of each cycle. On day 22 of cycle 2 or later, as soon as the absolute neutrophil count (ANC) is greater than 1000 cells/ul and platelets are greater than 50,000 cells/ul, patients receive hyper cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) for 2 additional cycles.
CYCLE 2 (AGE > 70 or unfit < 70): Starting in cycle 2, patients age > 70 or younger unfit patients for Hyper-CVAD receive ponatinib PO QD or dasatinib PO QD on days 1-21 of each cycle. Patients also receive methotrexate IV over 24 hours and IT on day 1, and cytarabine IV over 2 hours BID on days 2-3 of each cycle. Cycle 1 and 2 regimens are each repeated once starting on day 22 of cycle 2, or later, but as soon as the ANC is greater than 1000 cells/ul and platelets are greater than 50,000 cells/ul.
Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve remission (significant reduction in the amount of leukemia in bone marrow and blood/MRD negative) after 4 cycles may receive alternative treatment, either consolidation with two cycles of Hyper-CVAD followed by TKI maintenance therapy or undergo allogeneic stem cell transplantation followed by maintenance therapy. Patients who do not achieve a remission (MRD positive) are assigned to Arm D. Patients who experience un-resolving renal failure or life-threatening infection which may require a treatment delay of 21 days cross-over to Arm C to receive the prescribed course of blinatumomab.
ARM C (INDUCTION THERAPY):
CYCLE 1: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 29 or 30.
CYCLE 2: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 29 or 30.
Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM D (RE-INDUCTION): Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C.
ARM E (RE-INDUCTION): Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's age and the pre-specified chemotherapy arm.
Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care.
Patients are followed up every 3 months for first 2 years (from study registration), every 6 months for years 3-5, and then every 12 months for years 6-10.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Förenta staterna, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Förenta staterna, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Förenta staterna, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Förenta staterna, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Förenta staterna, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Förenta staterna, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Förenta staterna, 99504
- Anchorage Radiation Therapy Center
-
-
Arkansas
-
Fort Smith, Arkansas, Förenta staterna, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Burbank, California, Förenta staterna, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Clovis, California, Förenta staterna, 93611
- Community Cancer Institute
-
Clovis, California, Förenta staterna, 93611
- University Oncology Associates
-
Duarte, California, Förenta staterna, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Förenta staterna, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
La Jolla, California, Förenta staterna, 92093
- UC San Diego Moores Cancer Center
-
Orange, California, Förenta staterna, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06520
- Yale University
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30912
- Augusta University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Förenta staterna, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Förenta staterna, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Förenta staterna, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Förenta staterna, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Förenta staterna, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Förenta staterna, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Förenta staterna, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, Förenta staterna, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Förenta staterna, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, Förenta staterna, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Förenta staterna, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Förenta staterna, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Förenta staterna, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Förenta staterna, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Förenta staterna, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Förenta staterna, 62002
- OSF Saint Anthony's Health Center
-
Burr Ridge, Illinois, Förenta staterna, 60527
- Loyola Center for Health at Burr Ridge
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University
-
Evanston, Illinois, Förenta staterna, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Glenview, Illinois, Förenta staterna, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Förenta staterna, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Homer Glen, Illinois, Förenta staterna, 60491
- Loyola Medicine Homer Glen
-
Lake Forest, Illinois, Förenta staterna, 60045
- Northwestern Medicine Lake Forest Hospital
-
Maywood, Illinois, Förenta staterna, 60153
- Loyola University Medical Center
-
Melrose Park, Illinois, Förenta staterna, 60160
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Förenta staterna, 62864
- SSM Health Good Samaritan
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Iowa
-
Ames, Iowa, Förenta staterna, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Förenta staterna, 50010
- McFarland Clinic - Ames
-
Boone, Iowa, Förenta staterna, 50036
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Förenta staterna, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Förenta staterna, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Förenta staterna, 50158
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Förenta staterna, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Förenta staterna, 67530
- Central Care Cancer Center - Great Bend
-
Kansas City, Kansas, Förenta staterna, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Förenta staterna, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Förenta staterna, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
Louisville, Kentucky, Förenta staterna, 40245
- UofL Health Medical Center Northeast
-
-
Louisiana
-
Shreveport, Louisiana, Förenta staterna, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Bethesda, Maryland, Förenta staterna, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Förenta staterna, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Förenta staterna, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Förenta staterna, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Förenta staterna, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Förenta staterna, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Förenta staterna, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, Förenta staterna, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Förenta staterna, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Förenta staterna, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Förenta staterna, 48503
- Hurley Medical Center
-
Flint, Michigan, Förenta staterna, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Förenta staterna, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Förenta staterna, 48503
- Cancer Hematology Centers - Flint
-
Jackson, Michigan, Förenta staterna, 49201
- Allegiance Health
-
Livonia, Michigan, Förenta staterna, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb, Michigan, Förenta staterna, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Novi, Michigan, Förenta staterna, 48377
- Henry Ford Medical Center-Columbus
-
Pontiac, Michigan, Förenta staterna, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Förenta staterna, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Förenta staterna, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Saginaw, Michigan, Förenta staterna, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Förenta staterna, 48601
- MyMichigan Medical Center Saginaw
-
Shelby, Michigan, Förenta staterna, 48315
- Henry Ford Macomb Health Center - Shelby Township
-
Tawas City, Michigan, Förenta staterna, 48764
- MyMichigan Medical Center Tawas
-
West Bloomfield, Michigan, Förenta staterna, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Förenta staterna, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyandotte, Michigan, Förenta staterna, 48192
- Henry Ford Wyandotte Hospital
-
Ypsilanti, Michigan, Förenta staterna, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Förenta staterna, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Southhaven, Mississippi, Förenta staterna, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Förenta staterna, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Förenta staterna, 65613
- Central Care Cancer Center - Bolivar
-
City of Saint Peters, Missouri, Förenta staterna, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Förenta staterna, 63141
- Siteman Cancer Center at West County Hospital
-
Joplin, Missouri, Förenta staterna, 64804
- Freeman Health System
-
Joplin, Missouri, Förenta staterna, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Förenta staterna, 64132
- Research Medical Center
-
Rolla, Missouri, Förenta staterna, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Förenta staterna, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Förenta staterna, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Förenta staterna, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Förenta staterna, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Förenta staterna, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Förenta staterna, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Förenta staterna, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Förenta staterna, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Förenta staterna, 63128
- Mercy Hospital South
-
Washington, Missouri, Förenta staterna, 63090
- Mercy Hospital Washington
-
-
Montana
-
Missoula, Montana, Förenta staterna, 59802
- Saint Patrick Hospital - Community Hospital
-
-
New Jersey
-
Long Branch, New Jersey, Förenta staterna, 07740
- Monmouth Medical Center
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester
-
The Bronx, New York, Förenta staterna, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Förenta staterna, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Förenta staterna, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Förenta staterna, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Förenta staterna, 44109
- MetroHealth Medical Center
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Förenta staterna, 45069
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Förenta staterna, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Förenta staterna, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Förenta staterna, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Förenta staterna, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Förenta staterna, 97420
- Bay Area Hospital
-
Newberg, Oregon, Förenta staterna, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Förenta staterna, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Förenta staterna, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Förenta staterna, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Förenta staterna, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Förenta staterna, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Förenta staterna, 17822
- Geisinger Medical Center
-
East Stroudsburg, Pennsylvania, Förenta staterna, 18301
- Pocono Medical Center
-
Hazleton, Pennsylvania, Förenta staterna, 18201
- Lehigh Valley Hospital-Hazleton
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- UPMC Hillman Cancer Center
-
Wilkes-Barre, Pennsylvania, Förenta staterna, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Förenta staterna, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Förenta staterna, 29425
- Medical University of South Carolina
-
Easley, South Carolina, Förenta staterna, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Förenta staterna, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Förenta staterna, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Förenta staterna, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Förenta staterna, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Förenta staterna, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Förenta staterna, 29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Franklin, Tennessee, Förenta staterna, 37067
- Vanderbilt-Ingram Cancer Center Cool Springs
-
Memphis, Tennessee, Förenta staterna, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Förenta staterna, 37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Förenta staterna, 77030
- Houston Methodist Hospital
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Förenta staterna, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen, Washington, Förenta staterna, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Förenta staterna, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Förenta staterna, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Förenta staterna, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Förenta staterna, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Förenta staterna, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Förenta staterna, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Förenta staterna, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Förenta staterna, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Förenta staterna, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Förenta staterna, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Förenta staterna, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Förenta staterna, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Förenta staterna, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Förenta staterna, 98584
- Providence Regional Cancer System-Shelton
-
Vancouver, Washington, Förenta staterna, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Förenta staterna, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Förenta staterna, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Eau Claire, Wisconsin, Förenta staterna, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Förenta staterna, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Förenta staterna, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Förenta staterna, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Förenta staterna, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Förenta staterna, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Förenta staterna, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Förenta staterna, 54476
- Marshfield Medical Center - Weston
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Jerusalem, Israel, 91031
- Shaare Zedek Medical Center
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Puerto Rico, 00936
- San Juan City Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
ELIGIBILITY CRITERIA FOR PRE-REGISTRATION (TO STEP 0)
-
Patient must be >= 18 and =< 75 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-3
-
Patient must be newly diagnosed with B acute lymphoblastic leukemia (B-ALL) or is suspected to have acute lymphoblastic leukemia (ALL)
-
Patient must have BCR-ABL1 positive disease. The diagnosis of ALL and the presence of BCR-ABL translocation must be confirmed centrally. Patients can be registered and begin step 1 therapy while awaiting central laboratory eligibility confirmation
- NOTE: Bone marrow aspirate and/or peripheral blood specimen must be submitted to the ECOG-American College of Radiology Imaging Network (ACRIN) Leukemia Laboratory at MD Anderson Cancer Center to determine patient's eligibility for registration to Step 1 or confirm patient evaluability. Centrally fluorescence-activated cell sorting (FACS) analysis will be performed to determine B-ALL and to exclude acute myeloid leukemia (AML) or acute bi-phenotypic leukemia and baseline BCR-ABL status will be determined by fluorescent in situ hybridization (FISH). The ECOG-ACRIN Leukemia Laboratory will forward results within 48 hours of receipt of the specimen to the submitting institution. Bone marrow aspirate is to be from first pull (initial or re-direct). Specimens must contain sufficient blast cells. In cases where the bone marrow aspiration may be inadequate, or the bone marrow examination has already been performed prior to study consent and enrollment on Step 0, peripheral blood may be submitted, with recommendation that adequate circulating blasts are present (> 10%). If a diagnosis of BCR-ABL positive B-ALL has already been established by local Clinical Laboratory Improvement Act (CLIA) certified laboratories, the patient may be registered to step 1 without waiting for central confirmation
-
-
Patient must not have a diagnosis of BCR/ABL T-ALL
-
Patient must not have received chemotherapy for B-ALL. Patients who received up to five days of therapy (hydroxyurea and/or steroids of any kind) with the aim to reduce disease burden prior to study registration to Step 1 are eligible
-
Patient must not have unstable epilepsy that requires treatment
-
Patients with lymphoid blast crisis chronic myeloid leukemia (CML) are not eligible
-
ELIGIBILITY CRITERIA FOR REGISTRATION TO STEP 1
-
Patient must have a diagnosis of Philadelphia chromosome positive (Ph+) ALL that has been determined locally and bone marrow and/or peripheral blood was sent and receipt confirmed for central confirmation or determined centrally by the ECOG-ACRIN Leukemia Laboratory at MD Anderson Cancer Center
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any woman, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of step 1 registration, while on study treatment, and until at least six months after the last dose of study treatment
-
Total bilirubin =< 3 mg/dL (patients with Gilbert's syndrome must have a total bilirubin =< 5 mg/dL) (obtained =< 28 days prior to step 1 registration)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X the institutional upper limit of normal (ULN) (obtained =< 28 days prior to step 1 registration)
-
Estimated creatinine clearance > 45 mL/min (based on Cockcroft-Gault equation) (obtained =< 28 days prior to step 1 registration)
-
Patients with acute organ dysfunction at step 1 registration, which may be attributed to leukemia can be registered regardless of lab results at presentation. Such patients will be allowed to register and can start Arm A steroid + TKI therapy but will only be allowed to proceed to step 2 randomization if the eligibility criteria outlined is met
-
Patients who presented with no evidence of acute organ dysfunction but during step 0 experienced a rise in liver enzymes which investigator suspects to be a side effect of any of prescribed drugs, are allowed to be registered regardless of the level of liver enzymes. Step 2 randomization must be withheld until the eligibility criteria outline is met but no more than 14 days after concluding Arm A therapy
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable or on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have an undetectable HCV viral load and if indicated, on treatment
-
Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patient must not have active concomitant malignancy. Patients on chronic hormonal therapy for breast or prostate cancer or patients treated with maintenance with targeted agents but are in remission with no evidence for the primary malignancies are eligible
-
Patient must not have complaints of symptoms and/or have clinical and/or radiological signs that indicate an uncontrolled infection or any other concurrent medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better
-
Investigators must confirm which TKI patient is to receive
- NOTE: Patients with known T315I mutation status should receive ponatinib treatment
- NOTE: In situations due to insurance coverage issues and the pre-selected TKI is not immediately available, patients can receive dasatinib or imatinib during step 1. The investigator must re-specify dasatinib or ponatinib prior to step 2 randomization and from then on patients must receive the pre-selected TKI only
-
ELIGIBILITY CRITERIA FOR RANDOMIZATION TO STEP 2
-
Patient must have completed at least 7 and no more than 21 days of protocol-treatment on Arm A prior to step 2 randomization. (Days in which arm A therapy was withheld for any reason are not counted)
- NOTE: First day of steroids prescription after registration will be considered as the first day of study therapy. The selected TKI must be initiated prior to randomization
-
Patients who presented with acute organ dysfunction within 2 weeks of registration to step 1 must have total bilirubin =< 2 X institutional upper limit of normal (ULN)
-
AST(SGOT) and ALT(SGPT) =< 2 X the institutional upper limit of normal (ULN)
-
Estimated creatinine clearance > 45 mL/min (based on Cockcroft-Gault equation)
-
Investigators must confirm which TKI patient is to receive.
- NOTE: Patients with known T315I mutation status should receive ponatinib treatment
-
For patients under age 70, intended chemotherapy regimen must have been determined prior to randomization
-
Patient must not have active central nervous system (CNS) involvement by leukemic blasts. Patients with signs of CNS involvement at presentation are eligible for randomization if clearance of blasts from the cerebrospinal fluid (CSF) is demonstrated
-
Patients must have resolved any serious infectious complications related to therapy
-
Any significant medical complications related to therapy must have resolved
-
ELIGIBILITY CRITERIA FOR REGISTRATION TO STEP 3 (RE-INDUCTION)
-
Institution has received centralized MRD results confirming positive status
-
Patients who presented with acute organ dysfunction within 2 weeks of registration to step 1 must have total bilirubin =< 2 X institutional ULN
-
Patients who presented with acute organ dysfunction must have AST (SGOT)/ALT (SGPT) =< 2 X institutional upper limit of normal (ULN)
-
Patients who presented with acute organ dysfunction must have an estimated creatinine clearance > 45 mL/min (based on Cockcroft-Gault equation)
-
Investigators must confirm which TKI patient is to receive
- NOTE: Patients with known T315I mutation status should receive ponatinib treatment
-
For patients under age 70 and previously assigned to Arm C, intended chemotherapy regimen must have been determined
-
Step 3 (Re-Induction): Patients must have resolved any serious infectious complications related to therapy
-
Step 3 (Re-Induction): Any significant medical complications related to therapy must have resolved
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (steroid, TKI), Single Arm Pre-Induction
Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21 based on investigator's choice. |
Given PO
Andra namn:
Given PO
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo lumbar puncture
Andra namn:
Given PO
Andra namn:
Correlative studies
Andra namn:
Undergo bone marrow aspiration and biopsy Undergo ECG
Andra namn:
|
|
Experimentell: Arm B (steroid, TKI, chemotherapy)
See Detailed Description. |
Given IV
Andra namn:
Given IV
Andra namn:
Given PO
Andra namn:
Given IV
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo lumbar puncture
Andra namn:
Given PO
Andra namn:
Correlative studies
Andra namn:
Given PO or IV
Andra namn:
Undergo bone marrow aspiration and biopsy Undergo ECG
Andra namn:
Given IV or IT
Andra namn:
Given IV
Andra namn:
Given IV or IT
Andra namn:
|
|
Experimentell: Arm C (steroid, TKI, chemotherapy, immunotherapy)
CYCLE 1: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 29 or 30. CYCLE 2: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 29 or 30. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. |
Given PO
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Given IV
Andra namn:
Undergo lumbar puncture
Andra namn:
Given PO
Andra namn:
Correlative studies
Andra namn:
Given PO or IV
Andra namn:
Undergo bone marrow aspiration and biopsy Undergo ECG
Andra namn:
Given IV
Andra namn:
Given IV or IT
Andra namn:
|
|
Experimentell: Arm D (steroid, TKI, chemotherapy, immunotherapy)
Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C. Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care. |
Given IV
Andra namn:
Given PO
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Given IV
Andra namn:
Undergo lumbar puncture
Andra namn:
Given PO
Andra namn:
Correlative studies
Andra namn:
Given PO or IV
Andra namn:
Undergo bone marrow aspiration and biopsy Undergo ECG
Andra namn:
Given IV or IT
Andra namn:
|
|
Experimentell: Arm E (steroid, TKI, chemotherapy)
Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's age and the pre-specified chemotherapy arm. Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care. |
Given IV
Andra namn:
Given IV
Andra namn:
Given PO
Andra namn:
Given IV
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo lumbar puncture
Andra namn:
Given PO
Andra namn:
Correlative studies
Andra namn:
Given PO or IV
Andra namn:
Undergo bone marrow aspiration and biopsy Undergo ECG
Andra namn:
Given IV or IT
Andra namn:
Given IV or IT
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall survival (OS)
Tidsram: Time between randomization and death from any cause, assessed up to 10 years from the date of registration
|
Will compare OS following induction with steroids + tyrosine kinase inhibitor (TKI) + blinatumomab and induction with steroids + TKI + chemotherapy. Will be based on an intent-to-treat analysis. Estimates of OS including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Comparisons of OS between treatment arms will be conducted using the one-sided stratified log-rank test, stratified on the same factors used in the randomization. Cox proportional hazards models of OS, stratified on the same factors used in the randomization, will be used to assess the effect of treatment by adjusting other possible clinical and biological risk factors, including cytogenetic abnormalities. |
Time between randomization and death from any cause, assessed up to 10 years from the date of registration
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of minimal residual disease (MRD) negative complete remission (CR)
Tidsram: At the end of first induction (week 15)
|
Will be centrally evaluated. Will be compared between two arms using Fisher's exact test with a one-sided type I error rate of 2.5%. Multivariable logistic regression modeling will be used to adjust for other possible clinical and biological risk factors. For patients registered to Step 3 (re-induction), the rates of MRD negative CR and their corresponding 95% confidence intervals after re-induction will be given by treatment arm. |
At the end of first induction (week 15)
|
|
Event free survival (EFS)
Tidsram: Time from randomization to failure to achieve induction molecular remission by the end of first induction, confirmed molecular relapse after molecular remission or to death in remission, assessed up to 10 years from the date of registration
|
Will be based on an intent-to-treat analysis. Estimates of EFS including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Comparisons of EFS between treatment arms will be conducted using the one-sided stratified log-rank test, stratified on the same factors used in the randomization. Cox proportional hazards models of EFS, stratified on the same factors used in the randomization, will be used to assess the effect of treatment by adjusting other possible clinical and biological risk factors, including cytogenetic abnormalities |
Time from randomization to failure to achieve induction molecular remission by the end of first induction, confirmed molecular relapse after molecular remission or to death in remission, assessed up to 10 years from the date of registration
|
|
Rate of MRD negative CR
Tidsram: After re-induction
|
Will be centrally evaluated. Will be compared between two arms using Fisher's exact test with a one-sided type I error rate of 2.5%. Multivariable logistic regression modeling will be used to adjust for other possible clinical and biological risk factors. For patients registered to Step 3 (re-induction), the rates of MRD negative CR and their corresponding 95% confidence intervals after re-induction will be given by treatment arm. |
After re-induction
|
|
Incidence of adverse events
Tidsram: Up to 10 years from the date of registration
|
All toxicity grades and reportable adverse events will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Up to 10 years from the date of registration
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Yishai Ofran, ECOG-ACRIN Cancer Research Group
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Svavelföreningar
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Terapeutik
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Punktering
- Kirurgiska ingrepp, operativ
- Tiazoler
- Azoler
- Cytologiska tekniker
- Nukleinsyror, nukleotider och nukleosider
- Cytodiagnos
- Kolväten, acyklisk
- Kolväten
- Kolväten, cykliska
- Kolhydrater
- Alkaloider
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glykosider
- Förenad
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Steroider, fluorerade
- Alkan
- Bensiverivat
- Diagnostiska tekniker, kirurgiska
- Alkanesulfonater
- Alkanesulfonsyror
- Sulfonsyror
- Svavelsyror
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Nukleosider
- Pteriner
- Pteridiner
- Graviditet
- Gravidioder
- Vinca alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indoliziner
- Arabinonukleosider
- Aminopterin
- Anthracykliner
- Naftakener
- Aminoglykosider
- Daunorubicin
- Diagnostiska tekniker, neurologiska
- Bensensulfonater
- Arylsulfonater
- Arylsulfonsyror
- Sulfhydrylföreningar
- Dasatinib
- Dexametason
- Metotrexat
- Prednison
- Cyklofosfamid
- Cytarabin
- Doxorubicin
- Vincristine
- Mesna
- Kalciumdobesilat
- Biopsi
- Provhantering
- blinatumomab
- Ryggpunkter
- dexametason 21-fosfat
- deltacortene
- prednyliden
- N, N-dicyklohexyl-isoborneol-10-sulfonamid
- merfos
- auricularum
- dexametasonacetat
- ponatinib
Andra studie-ID-nummer
- NCI-2020-06381
- U10CA180820 (U.S.S. NIH-anslag/kontrakt)
- NCI-2020-06381 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- EA9181 (Annan identifierare: CTEP)
- EA9181 (Annan identifierare: ECOG-ACRIN Cancer Research Group)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .